KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Enterprise Value (2023 - 2025)

Biocryst Pharmaceuticals' Enterprise Value history spans 9 years, with the latest figure at -$274.7 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 26.99% year-over-year to -$274.7 million; the TTM value through Dec 2025 reached -$274.7 million, down 26.99%, while the annual FY2025 figure was -$274.7 million, 26.99% down from the prior year.
  • Enterprise Value reached -$274.7 million in Q4 2025 per BCRX's latest filing, down from -$129.4 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$129.4 million in Q3 2025 to a low of -$410.7 million in Q2 2023.
  • Average Enterprise Value over 3 years is -$258.0 million, with a median of -$249.3 million recorded in 2023.
  • The largest YoY upside for Enterprise Value was 60.8% in 2025 against a maximum downside of 26.99% in 2025.
  • A 3-year view of Enterprise Value shows it stood at -$280.1 million in 2023, then grew by 22.77% to -$216.3 million in 2024, then dropped by 26.99% to -$274.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Enterprise Value are -$274.7 million (Q4 2025), -$129.4 million (Q3 2025), and -$172.5 million (Q2 2025).